Cyclerion Therapeutics, Inc. (CYCN) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.14
-8% vs avg
5yr avg: 1.24
30Y Low0.5·High2.7
ROE
↑
-39.3%
↓+46% vs avg
5yr avg: -72.8%
30Y Low-282%·High-30%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CYCN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cyclerion Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14M | $4M | $8M | $8M | $29M | $67M | $93M | $74M | — | — |
| Enterprise Value | $11M | $855750 | $5M | $261300 | $15M | $13M | $84M | $51M | — | — |
| P/E Ratio → | -2.94 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.68 | 1.97 | 4.05 | — | 95.99 | 20.28 | 40.52 | 16.52 | — | — |
| P/B Ratio | 1.14 | 0.45 | 0.92 | 0.69 | 2.73 | 1.40 | 1.56 | 0.76 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CYCN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.41 | 2.44 | — | 50.94 | 4.03 | 36.75 | 11.27 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
CYCN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cyclerion Therapeutics, Inc. earns an operating margin of -239.8%. Operating margins have compressed from -181.4% to -239.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -39.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | -1778.5% | 100.0% | -2357.1% | -2010.9% | — | — |
| Operating Margin | -239.8% | -239.8% | -181.4% | — | -6242.4% | -1662.5% | -3539.4% | -2774.3% | — | — |
| Net Profit Margin | -170.1% | -170.1% | -152.8% | — | -14841.1% | -1555.6% | -3388.6% | -2729.3% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.3% | -39.3% | -30.4% | -48.4% | -150.2% | -95.9% | -99.0% | -281.9% | — | — |
| ROA | -36.1% | -36.1% | -26.6% | -33.5% | -113.9% | -59.1% | -51.5% | -126.9% | -1790.9% | -1717.0% |
| ROIC | -65.1% | -65.1% | -58.3% | -2468.4% | — | -183.5% | -97.6% | -294.9% | — | — |
| ROCE | -55.5% | -55.5% | -36.0% | -119.1% | -63.2% | -75.3% | -61.0% | -158.5% | — | — |
CYCN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.77 | 0.76 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.36 | -0.37 | -0.67 | -1.28 | -1.12 | -0.15 | -0.24 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -3394.63 | — | — | — | — |
Net cash position: cash ($3M) exceeds total debt ($0)
CYCN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cyclerion Therapeutics, Inc.'s current ratio of 5.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.85x to 5.15x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 | 3.45 | 5.55 | 0.05 | 0.09 |
| Quick Ratio | 5.15 | 5.15 | 5.83 | 3.85 | 1.94 | 4.92 | 3.45 | 5.55 | 0.05 | 0.09 |
| Cash Ratio | 3.60 | 3.60 | 4.46 | 3.63 | 1.75 | 4.87 | 3.21 | 5.35 | — | — |
| Asset Turnover | — | 0.21 | 0.21 | — | 0.02 | 0.06 | 0.02 | 0.02 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 175.99 | 101.47 | — | 117.98 | 10.99 | 20.19 | 119.37 | — | — |
CYCN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cyclerion Therapeutics, Inc. returns 0.9% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.9% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.9% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M |
Peer Comparison
Compare CYCN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CYCNYou | $14M | -2.9 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 ADMA | $2B | 13.8 | 9.6 | 69.2 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 KALA | $79M | -1.1 | — | — | — | — | -279.2% | — | — |
 PRTA | $468M | -2.0 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 MNKD | $1B | 197.0 | 31.6 | 88.9 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 AGIO | $2B | -4.8 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CYCN — Frequently Asked Questions
Quick answers to the most common questions about buying CYCN stock.
What is Cyclerion Therapeutics, Inc.'s P/E ratio?
Cyclerion Therapeutics, Inc.'s current P/E ratio is -2.9x. This places it at the 50th percentile of its historical range.
What is Cyclerion Therapeutics, Inc.'s ROE?
Cyclerion Therapeutics, Inc.'s return on equity (ROE) is -39.3%. The historical average is -106.4%.
Is CYCN stock overvalued?
Based on historical data, Cyclerion Therapeutics, Inc. is trading at a P/E of -2.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Cyclerion Therapeutics, Inc.'s profit margins?
Cyclerion Therapeutics, Inc. has 100.0% gross margin and -239.8% operating margin.